New IV drug hopes to regrow hair in severe alopecia

NCT ID NCT07533006

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4005130 (given intravenously)
What this could lead to: If it works, this could point toward a new treatment for severe hair loss from alopecia areata.
What could go wrong: This is an early phase 2 study with only 60 people. The drug may not work better than placebo, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

Beijing Friendship Hospital Affiliate of Capital University
NOT_YET_RECRUITING

Beijing, 100050, China
Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Center For Dermatology Clinical Research, Inc.
RECRUITING

Fremont, California, 94538, United States
Centrum Badan Klinicznych PI-House sp. z o.o.
RECRUITING

Gdansk, 80-546, Poland
Centrum Medyczne Ginemedica
RECRUITING

Wroclaw, 50-414, Poland
Chelsea and Westminster Hospital NHS Foundation Trust
NOT_YET_RECRUITING

London, SW10 9NH, United Kingdom
Chung-Ang University Hospital
NOT_YET_RECRUITING

Dongjak-gu, 06973, South Korea
Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
RECRUITING

Santa Clarita, California, 91355, United States
Dar Clinical Research - Ottawa - Hunt Club Road
RECRUITING

Ottawa, K1V 1C1, Canada
Dermedic Jacek Zdybski
RECRUITING

Ostrowiec Świętokrzyski, 27-400, Poland
Diamond Clinic
RECRUITING

Krakow, 31-559, Poland
Erasmus Medisch Centrum
NOT_YET_RECRUITING

Rotterdam, 3015 GD, Netherlands
Health Clinical Research, LLC
RECRUITING

Cutler Bay, Florida, 33189, United States
Huashan Hospital, Fudan University
NOT_YET_RECRUITING

Shanghai, 200040, China
Inha University Hospital
NOT_YET_RECRUITING

Incheon, 22332, South Korea
Jeonbuk National University Hospital
NOT_YET_RECRUITING

Jeonju, 54907, South Korea
Jordan Valley Dermatology & Research Center
RECRUITING

South Jordan, Utah, 84095, United States
Kelowna Health and Memory Centre
RECRUITING

Kelowna, V1Y 5A8, Canada
Kyung Hee University Hospital at Gangdong
NOT_YET_RECRUITING

Seoul, 05278, South Korea
Northridge Clinical Trials
RECRUITING

Northridge, California, 91325, United States
Revival Research Institute, LLC
RECRUITING

Troy, Michigan, 48084, United States
Royal London Hospital
NOT_YET_RECRUITING

London, E1 1FR, United Kingdom
Ryan Clinical Research Inc.
NOT_YET_RECRUITING

Newmarket, L3Y 5G8, Canada
SIMa Recherche
NOT_YET_RECRUITING

Verdun, H4G 2L8, Canada
Salford Royal Hospital
NOT_YET_RECRUITING

Salford, M6 8HD, United Kingdom
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, 03080, South Korea
Shanghai Skin Disease Hospital
NOT_YET_RECRUITING

Shanghai, 200071, China
Stracskin
RECRUITING

Portsmouth, New Hampshire, 03801, United States
Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
RECRUITING

San Antonio, Texas, 78235, United States
Tianjin Medical University General Hospital
NOT_YET_RECRUITING

Tianjin, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.